Thursday, January 12, 2017 11:38:27 AM
- PD said they plan to monetize TRACE technology this year
- PD said they will be announcing collaborations for TRACE via the TAP shortly
- On track to commence patient enrollment for registration trial in Q2 2017
- Plan is to move ahead with the registration trial with a multinational
- Exit opportunity may present itself within the next 18 months for lead program (EP IL-12 + anti-PD1)
- I understood the above statement as they will retain TRACE tech, and opportunities to partner it out beyond anti-PD1 candidates in the event of a sale of the lead candidate; PD talks about keeping a piece of the pie
Audio from the webcast to verify the above (30 mins):
https://event.webcasts.com/viewer/event.jsp?ei=1130360
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM